Antiviral Drugs Market Size, Share & Industry Analysis, By Drug Class (Protease Inhibitors, Polymerase Inhibitors, Integrase Inhibitors, Combination Drugs, Reverse Transcriptase Inhibitors, and Others), By Disease Indication (Hepatitis, Human Immunodeficiency Virus (HIV), Influenza, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channel) and Regional Forecast, 2019-2026 (Includes COVID-19 Business Impact)

                                          
We have updated Antiviral Drugs Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Antiviral Drugs market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Antiviral Drugs market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Antiviral Drugs Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Antiviral Drugs Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Antiviral Drugs Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

Gilead Sciences and GlaxoSmithKline to Lead the Market
In terms of revenue, Gilead Sciences dominated the antiviral agents market owing to the remarkable sale of its drugs such as Biktarvy, Harvoni, etc. Genvoya, a leading fixed dose combination antiretroviral drug by Gilead, accounted for a revenue of more than USD 4.5 billion in 2018, which propelled the market share of the company. Another leading combination called Triumeq by GSK, generated over USD 3.4 billion revenue in 2018, which has provided a strategic position to the company in global market. Another key player operating in the market is Abvie. The company is growing because of its significant performance in Hepatitis C.

List of key Companies Covered:

  
Gilead Sciences
  
GlaxoSmithKline
  
Abbvie, Inc.
  
Merck & Co., Inc.
  
Bristol-Myers Squibb Company
  
Janssen Pharmaceuticals, Inc.
  
Mylan N.V.
  
Novartis AG

 

REPORT COVERAGE

The antiviral therapy has evolved over the years and is expanding at a rapid rate with the introduction of effective therapeutics by key companies. Investment by key pharmaceutical manufacturers in the R&D aiming to eradicate the viruses that are resistant to the existing traditional antiviral therapy, is changing the scenario of antiviral therapeutics market. Moreover, strong pipeline of the companies is expected to boost the market growth in coming years. For instance, Gilead Sciences entered in an antiviral deal with Novartis to gain exclusive rights to preclinical programs involving candidates for the treatment of herpes viruses, human rhinovirus, and influenza.

The research report offers an in-depth analysis of the market. It further provides details on the prevalence of key viral infections for major countries, regulatory and reimbursement scenario for key countries, new product launches, and key industry developments, such as mergers, acquisitions, and partnerships. Information on drivers, opportunities, threats, and restraints of the market can further help stakeholders to gain valuable insights into the market. The report offers a detailed competitive landscape by presenting information on key players, along with their strategies, in the market.

Report Scope & Segmentation

 

Segmentation

By Drug Class

  
Protease Inhibitors
  
Polymerase Inhibitors
  
Integrase Inhibitors
  
Reverse Transcriptase Inhibitors
  
Combination Drugs
  
Others

By Disease Indication

  
Hepatitis
  
Human Immunodeficiency Virus (HIV)
  
Influenza
  
Others

By Distribution Channel

  
Hospital Pharmacy
  
Retail Pharmacy
  
Online Channel

By Geography

  
North America (U.S. and Canada)
  
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  
Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  
Latin America (Brazil, Mexico, and Rest of Latin America)
  
Middle East and Africa (South Africa, GCC, and Rest of Middle East & Africa)

INDUSTRY DEVELOPMENT:

April 2019: Gilead Sciences, one of the major antiviral drugs manufacturers, submitted a supplemental New Drug Application (sNDA) to the USFDA for Descovy, for pre-exposure prophylaxis, to reduce the risk of sexually acquired HIV infection among individuals who are HIV-negative and at risk for HIV.

December 2019: GlaxoSmithKline submitted a new drug application to the USFDA seeking approval for fostemsavir, an experimental treatment for HIV in adults.

August 2017: Abbvie received a USFDA approval for MAVYRET, a ribavirin-free treatment option for adults with chronic hepatitis C virus (HCV) infection.